- Topic
41k Popularity
59k Popularity
62k Popularity
17k Popularity
69k Popularity
- Pin
- 🎉【Gate Singapore Flagship Event · Square Fun Quiz Challenge Day 1】
#TOKEN2049# is just around the corner, and Gate is bringing the heat to Singapore!
Token of Love Music Festival, Gate x Oracle Red Bull Racing Reception, and the F1 Race Viewing are all set to roll out!
Join Square Fun Quiz Challenge now, test how much you know about the events and share $100 BTC in rewards!
To join: Comment your answers (format: 1B 2A 3B 4C)
🎁 Rewards: 3 lucky winners each day → $10 BTC each
👑 Bonus: Answer all questions correctly for 3 days → Extra $10 BTC for Super Quiz King!
📖 Day 1 · Quiz (Single Choic - 💥 Gate Square Event: #SOMI Creative Contest# 💥
Post original content related to SOMI or CandyDrop #76 on Gate Square for a chance to share 180 SOMI rewards!
CandyDrop 76: CandyDrop x Somnia (SOMI)👉 https://www.gate.com/announcements/article/46912
📅 Event Period: Sep 8, 2025 – Sep 15, 2025
📌 How to Participate:
Post original content related to SOMI or the CandyDrop event
Minimum 80 words
Add hashtag: #SOMI Creative Contest#
Include CandyDrop participation screenshot
🏆 Rewards:
🥇 1st Prize (1 winner): 60 SOMI
🥈 2nd Prize (3 winners): 30 SOMI each
🥉 3rd Prize (6 winners): 10 SOMI each
(T - 🚗 #GateSquareCommunityChallenge# Round 1 — Who Will Be The First To The Moon?
Brain challenge, guess and win rewards!
5 lucky users with the correct answers will share $50 GT! 💰
Join:
1️⃣ Follow Gate_Square
2️⃣ Like this post
3️⃣ Drop your answer in the comments
📅 Ends at 16:00, Sep 17 (UTC)
Lyon: Remains optimistic about the development of Stone Pharmaceutical Group, maintaining a "highly confident outperform the market" rating.
Jin10 data reported on May 30 that Lyon published a research report indicating that although the sales of Enbipusi from Shanghai Pharmaceuticals (01093.HK) faced challenges, the first quarter performance still met expectations, with a year-on-year net profit fall of 8.4%. It is believed that Shanghai Pharmaceuticals' profits have bottomed out in the first quarter. In addition to the market's focus on SYS6010, the management also revealed that there are two other products that will achieve potential licensing cooperation, each exceeding $5 billion in scale. Lyon expressed continued optimism about Shanghai Pharmaceuticals' development, believing that its early R&D pipeline is competitive globally and has a differentiated innovative drug platform, maintaining a "highly confident outperform the market" rating for Shanghai Pharmaceuticals, with a target price of HKD 13.8.